Monoamine Oxidase Inhibitor Toxicity in Emergency Medicine Follow-up

  • Author: Steven Marcus, MD; Chief Editor: Asim Tarabar, MD   more...
 
Updated: Jul 16, 2010
 

Further Inpatient Care

Maintain vigilance regarding recrudescence of fever and fluid requirements.

Because toxicity may be delayed in onset of overdose, admit the patient and observe in a monitored setting.

Next

Prognosis

Patients should recover without sequelae if no adverse reactions occur, such as renal failure, stroke, or refractory hypotension.

Previous
Next

Patient Education

All patients medicated with MAOIs should receive extensive education regarding drug and food interaction problems. Encourage them to have all of their prescriptive and nonprescriptive drugs dispensed from one pharmacy so that an accurate medication profile can be maintained.

Previous
 
Contributor Information and Disclosures
Author

Steven Marcus, MD  Professor, Department of Preventive Medicine and Community Health, Associate Professor, Department of Pediatrics, New Jersey Medical School, University of Medicine and Dentistry of New Jersey; Executive and Medical Director, New Jersey Poison Information and Education System; Consulting Staff, Departments of Pediatrics and Internal Medicine, University Hospital, University of Medicine and Dentistry of New Jersey; Consulting Staff, Department of Pediatrics, Newark Beth Israel Medical Center

Steven Marcus, MD is a member of the following medical societies: Academy of Medicine of New Jersey, American Academy of Clinical Toxicology, American Academy of Pediatrics, American College of Emergency Physicians, American College of Medical Toxicology, American Medical Association, and Medical Society of New Jersey

Disclosure: Nothing to disclose.

Coauthor(s)

Wirachin Hoonpongsimanont, MD  Resident Physician, Department of Emergency Medicine, University of Medicine and Dentistry of New Jersey

Wirachin Hoonpongsimanont, MD is a member of the following medical societies: American College of Emergency Physicians, Emergency Medicine Residents Association, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard Lavely, MD, JD, MS, MPH  Lecturer in Health Policy and Administration, Department of Public Health, Yale University School of Medicine

Richard Lavely, MD, JD, MS, MPH is a member of the following medical societies: American College of Emergency Physicians, American College of Legal Medicine, and American Medical Association

Disclosure: Nothing to disclose.

John T VanDeVoort, PharmD  Regional Director of Pharmacy, Sacred Heart & St. Joseph's Hospitals

John T VanDeVoort, PharmD is a member of the following medical societies: American Society of Health-System Pharmacists

Disclosure: Nothing to disclose.

Fred Harchelroad, MD, FACMT, FAAEM, FACEP  Chair, Department of Emergency Medicine, Director of Medical Toxicology, Allegheny General Hospital; Associate Professor, Department of Emergency Medicine, Drexel University College of Medicine

Disclosure: Nothing to disclose.

John D Halamka, MD, MS  Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center

John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Chief Editor

Asim Tarabar, MD  Assistant Professor, Director, Medical Toxicology, Department of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure: Nothing to disclose.

References

  1. Brunton LL, Lazo JS, Parker KL. Drug therapy of depression and anxiety disorders. In: Goodman and Gillman: The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill; 2006:429-459/chap17.

  2. Mills KC. Monoamine oxidase inhibitors. In: Tintinalli JE, Kelen GD, Stapczynski JS, Ma OJ, Cline DM, eds. Tintinalli's Emergency Medicine: A comprehensive Study Guide. 6th ed. New York: McGraw-Hill; 2004:160.

  3. Kokan L. Monoamine oxidase inhibitors. In: Goldfrank, Flomenbaum, Howland, Hoffman, Nelson, eds. Goldfrank's Toxicological Emergencies. 7th ed. New York: McGraw-Hill; 2002:885-900/chap60.

  4. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry. Feb 2003;64(2):208-14. [Medline].

  5. Preskorn SH. Why the transdermal delivery of selegiline (6 mg/24 hr) obviates the need for a dietary restriction on tyramine. J Psychiatr Pract. May 2006;12(3):168-72. [Medline].

  6. Nandagopal JJ, DelBello MP. Selegiline transdermal system: a novel treatment option for major depressive disorder. Expert Opin Pharmacother. Jul 2009;10(10):1665-73. [Medline]. [Full Text].

  7. Watson WA, Litovitz TL, Klein-Schwartz W, et al. 2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2004;22(5):335-404. [Medline]. [Full Text].

  8. Litovitz TL, Klein-Schwartz W, Dyer KS, et al. 1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 1998;16(5):443-97. [Medline]. [Full Text].

  9. Litovitz TL, Smilkstein M, Felberg L, et al. 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 1997;15(5):447-500. [Medline].

  10. Litovitz TL, Bailey KM, Schmitz BF, et al. 1990 annual report of the American Association of Poison Control Centers National Data Collection System. Am J Emerg Med. Sep 1991;9(5):461-509. [Full Text].

  11. Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AC. 2005 Annual Report of the American Association of Poison Control Centers' national poisoning and exposure database. Clin Toxicol (Phila). 2006;44(6-7):803-932. [Medline]. [Full Text].

  12. Bronstein AC, Spyker DA, Cantilena JR et al. 2007 Annual Report of the American Association of poison Control Centers' National Poison data System (NPDS):25th Annual Report. Clinical toxicology. 2008;46:927-1057. [Full Text].

  13. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2008 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 26th Annual Report. Clin Toxicol (Phila). Dec 2009;47(10):911-1084. [Medline]. [Full Text].

  14. Rowley M, Riutort K, Shapiro D, Casler J, Festic E, Freeman WD. Methylene blue-associated serotonin syndrome: a 'green' encephalopathy after parathyroidectomy. Neurocrit Care. 2009;11(1):88-93. [Medline].

  15. Schwiebert C, Irving C, Gillman PK. Small doses of methylene blue, previously considered safe, can precipitate serotonin toxicity. Anaesthesia. Aug 2009;64(8):924. [Medline].

  16. Khavandi A, Whitaker J, Gonna H. Serotonin toxicity precipitated by concomitant use of citalopram and methylene blue. Med J Aust. Nov 3 2008;189(9):534-5. [Medline].

  17. Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity:inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. BR J Pharmocol. 2007/11;152:946-951.

  18. Erich JL, Shih RD, O'Connor RE. "Ping-pong" gaze in severe monoamine oxidase inhibitor toxicity. J Emerg Med. Sep-Oct 1995;13(5):653-5. [Medline].

  19. Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache. Feb 2010;50(2):264-72. [Medline].

  20. Tepper SJ. Drug interactions in headache:what to watch for and why. www.AmericanHeadacheSociety.org. Available at http://www.achenet.org/education/patients/DrugInteractionsinHeadache.asp. Accessed 6/4/2010.

  21. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. Jul 15 2006;43(2):180-7. [Medline].

  22. Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med. Mar 1995;12(1):49-51. [Medline].

  23. Francois B, Marquet P, Desachy A, et al. Serotonin syndrome due to an overdose of moclobemide and clomipramine. A potentially life-threatening association. Intensive Care Med. Jan 1997;23(1):122-4. [Medline].

  24. Henry JA. Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf. Jun 1997;16(6):374-90. [Medline].

  25. Hernandez AF, Montero MN, Pla A, Villanueva E. Fatal moclobemide overdose or death caused by serotonin syndrome?. J Forensic Sci. Jan 1995;40(1):128-30. [Medline].

  26. Isbister GK, Hackett LP, Dawson AH, et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol. Oct 2003;56(4):441-50. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.